Holen Sie sich die Stockscreener-App
16.78
4.77%
-0.84
Handel nachbörslich:
16.78
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
T. Rowe Price lists 2.8 million shares in Bicara Therapeutics (BCAX) ownership amendment. - Stock Titan
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Bicara Therapeutics Inc.Common Stock (Nasdaq:BCAX) Detailed Stock Data - The Chronicle-Journal
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com Australia
Bicara Therapeutics' President Ryan Cohlhepp Reports Stock Option Exercise and Share Sales in Form 4 Filing - Kalkine Media
Bicara interim CEO sells 17,500 shares after option exercise | BCAX Insider Trading - Stock Titan
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight on Bicara stock By Investing.com - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Bicara stock - Investing.com
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - moomoo.com
New Bicara (NASDAQ: BCAX) share sale planned after July and August deals - Stock Titan
BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan
BCAX Form 4 FilingsBicara Therapeutics Inc. SEC Form 4 - Stock Titan
BCAX 424B FilingsBicara Therapeutics Inc. SEC 424B - Stock Titan
BCAX 8-K FilingsBicara Therapeutics Inc. SEC 8-K - Stock Titan
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Bicara Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Boston biotech Bicara signs sublease for Wayfair space - The Business Journals
Bicara (BCAX) Financial Results: Reported EPS Tops Expectations in the Latest Session; Share Move: The Stock Records a 0.50% Decrease in the Current UpdateDividend Cut Risk - vinanet.vn
How Bicara’s Leadership Overhaul and CEO Succession Plan Could Shape Bicara Therapeutics (BCAX) Investors - webull.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com
Jennifer Larson Net Worth (2026) - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets - MarketBeat
BMO Capital Initiates Bicara Therapeutics at Outperform - Moomoo
Bicara Therapeutics Initiated at Outperform by BMO Capital - Moomoo
Bicara Therapeutics Inc. (BCAX) Stock Price, News, Quote & History - Yahoo Finance
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35 - Bitget
Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul - Yahoo Finance
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com India
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com Canada
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential - Investing.com
BMO Capital Initiates Bicara Therapeutics at Outperform - marketscreener.com
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - Sahm
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX - MarketBeat
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf FilingHas The Bull Case Changed? - webull.com
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX - MarketBeat
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson - Stock Titan
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3 - Stock Titan
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
0.00%
4.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):